-
High-Dose Sequential Therapy and Single Autologous Transplantation for Multiple Myeloma
Not Recruiting
More
This study uses a sequence of high-dose chemotherapy drugs and a stem cell transplant to
treat multiple myeloma. The study is being performed to evaluate the efficacy and side
effects of treatment. Specifically, the study is designed to reduce the risk of interstitial
pneumonitis.
Stanford is currently not accepting patients for this trial.
For more information, please contact BMT Referrals, 6507230822.
Lead Sponsor
Stanford Investigators
View full details
-
Sirolimus & Mycophenolate Mofetil as GvHD Prophylaxis in Myeloablative, Matched Related Donor HCT
Not Recruiting
More
A continuation study of sirolimus and mycophenolate mofetil (MMF) for graft-vs-host disease
(GvHD) prophylaxis for patients undergoing matched related allogeneic hematopoietic stem cell
transplantation (HSCT) for acute and chronic leukemia, myelodysplastic syndrome (MDS), high
risk non-Hodgkin lymphoma (NHL), or Hodgkin lymphoma (HL)
Stanford is currently not accepting patients for this trial.
For more information, please contact BMT Referrals, 6507230822.
Lead Sponsor
Stanford Investigators
View full details
-
Ph II of Non-myeloablative Allogeneic Transplantation Using TLI & ATG In Patients w/ Cutaneous T Cell Lymphoma
Not Recruiting
More
Non-myeloablative approach for allogeneic transplant is a reasonable option, especially given
that the median age at diagnosis is 55-60 years and frequently present compromised skin in
these patients, which increases the risk of infection. Therefore, we propose a clinical study
with allogeneic hematopoietic stem cell transplantation (HSCT) using a unique
non-myeloablative preparative regimen, TLI/ATG, to treat advanced mycosis fungoides/Sezary
syndrome (MF/SS).
Stanford is currently not accepting patients for this trial.
For more information, please contact Michelle Chin, 650-721-4183.
Lead Sponsor
Stanford Investigators
View full details
-
Autologous Followed by Non-myeloablative Allogeneic Transplantation for Non-Hodgkin's Lymphoma
Not Recruiting
More
The purpose of this trial is to develop an alternative treatment for patients with poor risk
non-Hodgkin's lymphoma. This trial uses a combination of high dose chemotherapy with stem
cell transplant using the patient's own cells. This is followed with non-myeloablative
transplant using stem cells from a related or unrelated donor to try and generate an
anti-lymphoma response from the new immune system.
Stanford is currently not accepting patients for this trial.
For more information, please contact Physician Referrals, 650-723-0822.
Lead Sponsor
Stanford Investigators
View full details
-
A Phase 2 Trial of Rituximab and Corticosteroid Therapy for Newly Diagnosed Chronic Graft Versus Host Disease
Not Recruiting
More
The addition of rituximab to prednisone for the initial treatment of chronic GVHD will
increase the overall response rate, enable a more rapid and effective steroid taper.
Stanford is currently not accepting patients for this trial.
For more information, please contact BMT Referrals, 6507230822.
Lead Sponsor
Stanford Investigators
View full details
-
Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder
Not Recruiting
More
RATIONALE: Cyclosporine eye drops may prevent graft-versus-host disease of the eye in
patients who have undergone donor stem cell transplant for hematologic cancer or bone marrow
failure disorder.
PURPOSE: This randomized phase I trial is studying how well cyclosporine eye drops work in
preventing graft-versus-host disease of the eye in patients who have undergone donor stem
cell transplant for hematologic cancer or bone marrow failure disorder.
Stanford is currently not accepting patients for this trial.
For more information, please contact Joanne Otani, 6507212372.
Stanford Investigators
View full details
-
CIBMTR Research Database
Recruiting
More
The primary purpose of the Research Database is to have a comprehensive source of
observational data that can be used to study HSC transplantation and cellular therapies.
A secondary purpose of the Research Database is to have a comprehensive source of data to
study marrow toxic injuries.
Objectives:
To learn more about what makes stem cell transplants and cellular therapies work well such
as:
- Determine how well recipients recover from their transplants or cellular therapy;
- Determine how recovery after a transplant or cellular therapy can be improved;
- Determine how a donor's or recipient's genetics impact recipient recovery after a
transplant or cellular therapy;
- Determine how access to transplant or cellular therapy for different groups of patients
can be improved;
- Determine how well donors recover from the collection procedures.
Stanford Investigators
View full details
-
Phase 1-2 of a CpG-Activated Whole Cell Vaccine Followed by Autologous Immunotransplant for MCL
Not Recruiting
More
Mantle cell lymphoma (MCL) is a sub-type of non-Hodgkin's lymphoma (NHL) which is generally
considered incurable with current therapy. Participants will receive an autologous vaccine
against their individual lymphoma after undergoing stem cell transplantation. This
vaccination may prolong the time which patients will stay in remission from their disease.
Stanford is currently not accepting patients for this trial.
For more information, please contact Ami Okada, 6507254968.
Stanford Investigators
View full details
-
Chronic Graft-versus-Host Disease Treatment (BMT CTN 0801)
Not Recruiting
More
This study is designed as a combined Phase II/III, randomized, open label, multicenter,
prospective comparative study of sirolimus plus prednisone versus
sirolimus/calcineurin-inhibitor plus prednisone for the treatment of chronic GVHD. Patients
will be stratified by transplant center and will be randomized to an experimental arm of one
of the two pre-specified experimental arms (sirolimus + prednisone or the comparator arm of
sirolimus + calcineurin inhibitor + prednisone) in a 1:1 ratio.
Stanford is currently not accepting patients for this trial.
For more information, please contact Physician Referrals, 650-723-0822.
Stanford Investigators
View full details
-
Defibrotide for Patients With Hepatic Veno-occlusive Disease: A Treatment IND Study
Not Recruiting
More
Single arm, open-label study to provide Defibrotide to patients diagnosed with VOD.
Defibrotide is no longer available though the Emergency Use IND mechanism (also known as
compassionate use, or single patient named use). This protocol is the only mechanism by which
Defibrotide can be made available to patients in the U.S.
Stanford is currently not accepting patients for this trial.
For more information, please contact Physician Referrals, 650-723-0822.
Stanford Investigators
View full details
-
Donor Regulatory T Cells in Treating Patients With Visceral Acute Graft-versus-Host Disease After Stem Cell Transplant
Not Recruiting
More
This phase I trial studies the side effects and best dose of donor regulatory T cells in
treating patients with graft-versus-host disease affecting the liver or gastrointestinal
organs (visceral) within 100 days (acute) after undergoing a stem cell transplant.
Graft-versus-host disease occurs when donor immune cells infused in a stem cell transplant
attack the gut, skin, liver, or other organ systems of the patient. Regulatory T cells are a
type of immune cell that may be able to reduce the attack of the donor's immune cells on the
patient's normal cells and help treat graft-vs-host disease.
Stanford is currently not accepting patients for this trial.
For more information, please contact Joanne Otani, 650-721-2372.
Stanford Investigators
View full details
-
Stem Cell Transplant With Lenalidomide Maintenance in Patients With Multiple Myeloma (BMT CTN 0702)
Not Recruiting
More
The study is designed as a Phase III, multicenter trial of tandem autologous transplants plus
maintenance therapy versus the strategy of single autologous transplant plus consolidation
therapy with lenalidomide, bortezomib and dexamethasone (RVD) followed by maintenance therapy
or single autologous transplant plus maintenance therapy as part of upfront treatment of
multiple myeloma (MM). Lenalidomide will be used as maintenance therapy for three years in
all arms.
Stanford is currently not accepting patients for this trial.
For more information, please contact Physician Referrals, 6507230822.
Stanford Investigators
View full details
-
Autologous Stem Cell Rescue for Primary Amyloidosis
Not Recruiting
More
To evaluate the role of high dose therapy and autologous hematopoietic cell transplant for
amyloidosis.
Stanford is currently not accepting patients for this trial.
For more information, please contact BMT Referrals, 6507230822.
Lead Sponsor
Stanford Investigators
View full details
-
A Phase 3 Study of Brentuximab Vedotin (SGN-35) in Patients at High Risk of Residual Hodgkin Lymphoma Following Stem Cell Transplant (The AETHERA Trial)
Not Recruiting
More
This is a randomized, double-blind, placebo-controlled, multicenter phase 3 trial to evaluate
the efficacy and safety of brentuximab vedotin (SGN-35) and best supportive care (BSC)
compared to placebo and BSC in treatment of residual Hodgkin lymphoma (HL) following
autologous stem cell transplant (ASCT).
Stanford is currently not accepting patients for this trial.
For more information, please contact Sarah Robeson, 6507251647.
Stanford Investigators
View full details
-
Gemcitabine and Hodgkin's Disease Chemotherapy Followed by Peripheral Blood Stem Cell Rescue for Hodgkin's Disease
Not Recruiting
More
This is a phase 2 study of gemcitabine + high-dose chemotherapy followed by peripheral blood
stem cell (PBSC) rescue for Hodgkin's Disease
Stanford is currently not accepting patients for this trial.
For more information, please contact BMT Referrals, 6507230822.
Lead Sponsor
Stanford Investigators
View full details
-
A Pilot Study of Imatinib Mesylate in Steroid Refractory Chronic Graft Versus Host Disease
Not Recruiting
More
To determine if subjects with steroid refractory cGVHD can tolerate imatinib mesylate and
whether their cGVHD responds to imatinib mesylate.
Stanford is currently not accepting patients for this trial.
For more information, please contact Joanne Otani, 6507212372.
Stanford Investigators
View full details
-
Phase 1 Nilotinib in Steroid Dependent/Refractory Chronic Graft Versus Host Disease
Not Recruiting
More
PRIMARY OBJECTIVES:
Determine the safety and tolerability of nilotinib in steroid dependent / refractory cGVHD.
SECONDARY OBJECTIVES:
Determine the clinical efficacy of nilotinib in steroid dependent / refractory cGVHD.
Stanford is currently not accepting patients for this trial.
For more information, please contact Joanne Otani, 650-721-2372.
Lead Sponsor
Stanford Investigators
View full details
-
Phase 2 Trial of Prophylactic Rituximab Therapy for Prevention of CGVHD
Not Recruiting
More
To determine if rituximab administered after allogeneic transplantation decreases the
incidence of chronic graft-vs-host disease (cGvHD)
Stanford is currently not accepting patients for this trial.
For more information, please contact Kate Tierney, 6507257063.
Lead Sponsor
Stanford Investigators
View full details
-
Phase 2 Poor Risk DLBCL of TLI and ATG Followed by Matched Allogeneic HT as Consolidation to Autologous HCT
Not Recruiting
More
The purpose of this study is to determine if double autologous then allogeneic hematopoietic
cell transplant may offer an improved treatment option for patients with relapsed diffuse
large B-cell lymphoma (DLBCL) who are not likely to be cured by the conventional
transplantation regimen.
Stanford is currently not accepting patients for this trial.
For more information, please contact BMT Referrals, 6507230822.
Lead Sponsor
Stanford Investigators
View full details
-
Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Chronic Graft Versus Host Disease
Not Recruiting
More
The purpose of this study is to assess the safety and clinical efficacy of ibrutinib in
subjects with steroid dependent or refractory Chronic Graft Versus Host Disease.
Stanford is currently not accepting patients for this trial.
For more information, please contact Janet McDowell, 650-725-1647.
Stanford Investigators
View full details
-
Phase 2 Study of Autologous Followed by Nonmyeloablative Allogeneic Transplantation Using TLI & ATG
Not Recruiting
More
To evaluate the toxicity and tolerability of this tandem autologous/allogeneic transplant
approach for patients with advanced stage multiple myeloma.
Stanford is currently not accepting patients for this trial.
For more information, please contact BMT Referrals, 6507230822.
Lead Sponsor
Stanford Investigators
View full details
-
Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients
Not Recruiting
More
The purpose of this study is to (1) demonstrate the efficacy and safety (toxicity) of 25
mg/kg/day of Defibrotide in patients with severe veno-occlusive disease (sVOD) and (2)
evaluate serum and endothelial markers of veno-occlusive disease (VOD) through the analysis
of blood samples.
Stanford is currently not accepting patients for this trial.
For more information, please contact BMT Referrals, 6507230822.
Stanford Investigators
View full details
-
Vaccine Therapy for Multiple Myeloma Utilizing Idiotype-Pulsed Allogeneic Dendritic Cells
Not Recruiting
More
Patients with Multiple myeloma who have undergone non-myeloablative allogeneic stem cell
transplant will receive 6 vaccinations of donor derived dendritic cells combined with
specific protein produced by multiple myeloma.
Stanford is currently not accepting patients for this trial.
For more information, please contact BMT Referrals, 6507230822.
Lead Sponsor
Stanford Investigators
View full details
-
Allogeneic Transplantation Using Total Lymphoid Irradiation (TLI) and Anti-Thymocyte Globulin (ATG) for Older Patients With Hematologic Malignancies
Not Recruiting
More
To measure how frequently and to what degree a complication of transplant cell acute graft
versus host disease (GvHD) occurs.
Stanford is currently not accepting patients for this trial.
For more information, please contact Physician Referrals, 650-723-0822.
Lead Sponsor
Stanford Investigators
View full details
-
Nilotinib and Imatinib Mesylate After Donor Stem Cell Transplant in Treating Patients With ALL or CML
Not Recruiting
More
This phase I/II trial is studying the side effects and best way to give nilotinib when given
alone or sequentially after imatinib mesylate after donor stem cell transplant in treating
patients with acute lymphoblastic leukemia or chronic myelogenous leukemia. Nilotinib and
imatinib mesylate may stop the growth of cancer cells by blocking some of the enzymes needed
for cell growth.
Stanford is currently not accepting patients for this trial.
For more information, please contact Physician Referrals, 6507230822.
Stanford Investigators
View full details
-
High Dose Sequential Therapy and Autologous Stem Cell Rescue for Multiple Myeloma
Not Recruiting
More
To assess the role of autologous hematopoietic cell rescue in the treatment of multiple
myeloma.
Stanford is currently not accepting patients for this trial.
For more information, please contact BMT Referrals, 6507230822.
Lead Sponsor
Stanford Investigators
View full details
-
Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation
Not Recruiting
More
The purpose of this research study is to better understand the onset and course of graft
versus host disease (GVHD)and other immune-mediated disorders after stem cell transplant.
Stanford is currently not accepting patients for this trial.
For more information, please contact Physician Referrals, 650-723-0822.
Stanford Investigators
View full details
-
Phase 1-2 MAHCT w/ TCell Depleted Graft w/ Simultaneous Infusion Conventional and Regulatory T Cell
Not Recruiting
More
For patients with hematologic malignancies undergoing allogeneic myeloablative (MA) HCT with
a T cell depleted graft, the infusion of naturally occurring regulatory T cells with
conventional T cells (T cell add back) in pre-defined doses and ratios will reduce the
incidence of acute graft vs host disease while augmenting the graft vs leukemia effect and
improving immune reconstitution.
Stanford is currently not accepting patients for this trial.
For more information, please contact Physician Referrals, 650-723-0822.
Stanford Investigators
View full details
-
Double Cord Versus Haploidentical (BMT CTN 1101)
Not Recruiting
More
Hematopoietic cell transplants (HCT)are one treatment option for people with leukemia or
lymphoma. Family members,unrelated donors or banked umbilical cordblood units with similar
tissue type can be used for HCT. This study will compare the effectiveness of two new types
of bone marrow transplants in people with leukemia or lymphoma: one that uses bone marrow
donated from family members with only partially matched bone marrow; and, one that uses two
partially matched cord blood units.
Stanford is currently not accepting patients for this trial.
For more information, please contact Physician Referrals, 650-723-0822.
Stanford Investigators
View full details
-
Imatinib and Rituximab in Treating Cutaneous Sclerosis in Patients With Chronic Graft-Versus-Host Disease
Not Recruiting
More
This randomized phase II trial is evaluating how well imatinib mesylate works compared to
rituximab in treating cutaneous sclerosis in patients with chronic graft- versus-host disease
(GVHD). Both imatinib and rituximab have been reported to decrease skin thickening and
improve skin and joint flexibility in people with cutaneous sclerosis due to chronic GVHD.
Stanford is currently not accepting patients for this trial.
For more information, please contact Physician Referrals , 650-723-0822.
Stanford Investigators
View full details
-
Intravenous Administration of RGI-2001 in Patient Undergoing Allogenic Hematopoietic Stem Cell Transplantation (AHSCT)
Not Recruiting
More
The clinical trial is a Phase 1/2a, open-label, multi-center, dose-escalation study to
evaluate the safety, tolerability and pharmacokinetic profile of RGI-2001 in patients
undergoing AHSCT, with radiation or non-radiation myeloablative preparative treatment.
The study will be separated into two parts; a dose escalation phase to assess safety,
followed by a large expansion phase to further evaluate the pharmacologic effects of either a
Maximum Tolerated Dose, Maximum Feasible Dose or optimal pharmacologically active dose of
RGI-2001. The initial dose escalation safety portion of the study (Part 1) will include
higher risk patients and limit the unrelated donor transplants. After safety is established
in part 1 of the study, the second portion of the study will expand the enrollment criteria
and allow transplantation by either related or unrelated donors.
This study will endeavor to identify the dose range at which RGI-2001 has an acceptable
safety profile, at which biologic activity is observed, and to guide possible dose levels to
utilize in later phase studies based on biological activity.
Stanford is currently not accepting patients for this trial.
For more information, please contact Physician Referrals, 6507230822.
Stanford Investigators
View full details
-
Post T-plant Infusion of Allogeneic Cytokine Induced Killer (CIK) Cells as Consolidative Therapy in Myelodysplastic Syndromes/Myeloproliferative Disorders
Not Recruiting
More
Allogeneic stem cell transplantation (transplant of blood cells from another individual) is a
treatment option for patients with myelodysplasia or myeloproliferative Disorders. During the
course of this study, it will be evaluated whether a particular type of blood cell, called a
cytokine-induced killer (CIK) cell, may add benefit to allogeneic stem cell transplantation.
CIK cells are present in small quantities in the bloodstream but their numbers can be
expanded after a brief period of nurturing in a laboratory.
Stanford is currently not accepting patients for this trial.
For more information, please contact Physician Referrals, 650-723-0822.
Stanford Investigators
View full details
-
Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203)
Not Recruiting
More
Acute Graft-versus-Host-Disease (GVHD) is an important cause of morbidity and mortality after
allogeneic hematopoietic stem cell transplantation (HSCT). This study aims to determine if
any of three new GVHD prophylaxis approaches improves the rate of GVHD and relapse free
survival at one year after transplant compared to the current standard prophylaxis regimen.
Stanford is currently not accepting patients for this trial.
For more information, please contact Physician Referrals, 650-723-0822.
Stanford Investigators
View full details
-
Chronic GVHD Response Measures Validation
Not Recruiting
More
The purpose of this study is to develop and validate endpoint measures that can accurately
determine whether patients are responding to treatment for chronic Graft-versus-Host Disease
(GVHD). Hopefully, this will also lead to being better able to predict which patients will
respond to what therapies.
Stanford is currently not accepting patients for this trial.
For more information, please contact Physician Referrals, 650-723-0822.
Stanford Investigators
View full details
-
Bone Marrow Grafting for Leukemia and Lymphoma
Recruiting
More
The purpose of this study is to obtain tissue samples for ongoing studies regarding
transplant outcomes and complications.
Lead Sponsor
Stanford Investigators
View full details
-
Phase 1 Infused Donor T Regulatory Cells in Steroid Dependent/Refractory Chronic GVHD
Not Recruiting
More
Chronic graft versus host disease (cGVHD) is a common complication of bone marrow or
hematopoietic cell transplant from another person (allogeneic transplant). This study will
determine if subjects with steroid dependent/refractory cGVHD can tolerate infusion of donor
regulatory T cells and whether their cGVHD responds to the infusion.
Stanford is currently not accepting patients for this trial.
For more information, please contact Joanne Otani, 650-721-2372.
Stanford Investigators
View full details
-
Sirolimus/Tacrolimus Versus Tacrolimus/Methotrexate for Preventing Graft-Versus-Host Disease (GVHD) (BMT CTN 0402)
Not Recruiting
More
The study is designed as a phase III, randomized, open label, multicenter, prospective,
comparative trial of sirolimus and tacrolimus versus tacrolimus and methotrexate as
graft-versus-host disease (GVHD) prophylaxis after human leukocyte antigen (HLA)-matched,
related, peripheral blood stem cell transplantation in individuals with hematologic cancer.
Participants will be stratified by transplant center and will be randomly assigned to the
sirolimus/tacrolimus or tacrolimus/methotrexate arms at a 1:1 ratio.
Stanford is currently not accepting patients for this trial.
For more information, please contact BMT Referrals, 6507230822.
Stanford Investigators
View full details
-
CD8+ Memory T-Cells as Consolidative Therapy After Donor Non-myeloablative Hematopoietic Cell Transplant in Treating Patients With Leukemia or Lymphoma
Not Recruiting
More
This phase 2 trial studies how well cluster of differentiation 8 (CD8)+ memory T-cells work
as a consolidative therapy following a donor non-myeloablative hematopoietic cell transplant
in treating patients with leukemia or lymphoma. Giving total lymphoid irradiation and
anti-thymocyte globulin before a donor hematopoietic cell transplant helps stop the growth of
cells in the bone marrow, including normal blood-forming cells (stem cells) and cancer cells.
When the healthy stem cells from a donor are infused into the patient they may help the
patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets.
Sometimes the transplanted cells from a donor can make an immune response against the body's
normal cells (called graft-versus-host disease). Giving cyclosporine and mycophenolate
mofetil after the transplant may stop this from happening. Once the donated stem cells begin
working, the patient's immune system may see the remaining cancer cells as not belonging in
the patient's body and destroy them. Giving an infusion of the donor's white blood cells,
such as CD8+ memory T-cells, may boost this effect and may be an effective treatment to kill
any cancer cells that may be left in the body (consolidative therapy).
Stanford is currently not accepting patients for this trial.
For more information, please contact Leah Galvez, 650-725-7951.
Stanford Investigators
View full details
-
Sirolimus as Treatment of Steroid-Refractory or Steroid-Dependent Chronic Graft-Versus-Host Disease
Not Recruiting
More
To study the effectiveness of an immunosuppressive drug sirolimus, in the treatment of
chronic graft versus host disease in combination with prednisone.
Stanford is currently not accepting patients for this trial.
For more information, please contact BMT Referrals, 6507230822.
Lead Sponsor
Stanford Investigators
View full details
-
Peripheral Blood Stem Cell Transplant vs Bone Marrow Transplant in Individuals With Hematologic Cancers (BMT CTN 0201)
Not Recruiting
More
The study is designed as a Phase III, randomized, open label, multicenter, prospective,
comparative trial of granulocyte colony stimulating factor (G-CSF)-mobilized peripheral blood
stem cells (PBSC) versus marrow from unrelated donors for transplantation in patients with
hematologic malignancies. Recipients will be stratified by transplant center and disease risk
and will be randomized to either the PBSC or marrow arm in a 1:1 ratio.
Stanford is currently not accepting patients for this trial.
For more information, please contact Kate Tierney, 6507257063.
Stanford Investigators
View full details
-
High Dose Chemotherapy and Allogeneic Hematopoietic Cell Transplant for Non-Hodgkin's Lymphoma
Not Recruiting
More
To evaluate the role of allogeneic hematopoietic cell transplantation in the treatment of
NHL.
Stanford is currently not accepting patients for this trial.
For more information, please contact BMT Referrals, 6507230822.
Lead Sponsor
Stanford Investigators
View full details
-
Trial to Evaluate Palifermin in the Reduction of Acute Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Allogeneic Marrow/Peripheral Blood Progenitor Cell (PBPC) Transplantation
Not Recruiting
More
The main purpose of this study is to evaluate the effect of palifermin versus placebo in the
reduction of severe acute graft versus host disease (GVHD) and severe oral mucositis.
Stanford is currently not accepting patients for this trial.
For more information, please contact BMT Referrals, 6507230822.
Stanford Investigators
View full details
-
Sirolimus & Mycophenolate Mofetil as GVHD Prophylaxis in Myeloablative, Matched Related Donor HCT
Not Recruiting
More
GVHD prophylaxis of sirolimus and mycophenolate mofetil for patients undergoing matched
related allogeneic transplant for acute and chronic leukemia, MDS, high risk NHL and HL
Stanford is currently not accepting patients for this trial.
For more information, please contact BMT Referrals, 6507230822.
Lead Sponsor
Stanford Investigators
View full details
-
Mixed Chimera Allogeneic Transplantation From Matched Unrelated Donors For The Treatment Of Multiple Myeloma
Not Recruiting
More
The purpose of the study is to determine the toxicity and feasibility of non-myeloablative
allogeneic hematopoietic cell transplants for multiple myeloma from unrelated donors.
Stanford is currently not accepting patients for this trial.
For more information, please contact BMT Referrals, 6507230822.
Lead Sponsor
Stanford Investigators
View full details
-
Autologous Bone Marrow Transplantation in Acute Non-Lymphoblastic Leukemia During First or Subsequent Remission
Not Recruiting
More
Evaluate the role of high dose chemotherapy with autologous hematopoietic cell
transplantation for AML.
Stanford is currently not accepting patients for this trial.
For more information, please contact BMT Referrals, 6507230822.
Lead Sponsor
Stanford Investigators
View full details
-
Post-transplant Autologous Cytokine-induced Killer (CIK) Cells for Treatment of High Risk Hematologic Malignancies
Not Recruiting
More
The purpose of the study is to conduct a phase I study of adoptive immunotherapy with
autologous, ex-vivo expanded cytokine-induced killer (CIK) cells to reduce the relapse rate
in autologous stem cell transplant patients with high-risk hematologic malignancies.
Stanford is currently not accepting patients for this trial.
For more information, please contact Sherry Moore, 6507257951.
Stanford Investigators
View full details
-
Allogeneic HCT Using Nonmyeloablative Host Conditioning With TLI & ATG vs SOC in AML
Not Recruiting
More
Acute myeloid leukemia (AML) is a cancer of the bone marrow that mostly affects older adults.
Even with the best chemotherapy, two-year disease-free survival is achieved in a minority of
patients. Bone marrow transplantation from a sibling donor may improve cure rates; however,
patients over 50 years of age have a high risk of complications and therefore generally are
excluded from this treatment option. Recently our group developed a transplantation strategy
for older cancer patients that protects against transplant-associated complications, yet does
not interfere with the ability of the transplanted donor cells to destroy cancer cells. With
this new method, we can now safely evaluate transplantation as a curative therapy for AML
patients over the age of 50. We have assembled clinical and scientific researchers throughout
the state of California to study and compare bone marrow transplantation using our new
approach with the best standard of care chemotherapy in AML patients over the age of 50. The
results of this study have the potential to establish a new treatment standard that will
improve survival of older AML patients.
Stanford is currently not accepting patients for this trial.
For more information, please contact BMT Referrals, 650-725-1647.
Lead Sponsor
Stanford Investigators
View full details
-
Prophylactic Use of Maribavir for the Prevention of Cytomegalovirus (CMV) Disease in Stem Cell Transplant Recipients
Not Recruiting
More
The purpose of this research study is to investigate whether or not maribavir is safe and
effective for preventing CMV disease when taken by mouth for up to 12 weeks in patients who
have had a stem cell transplant.
Stanford is currently not accepting patients for this trial.
For more information, please contact Janice Brown, 6507230822.
Stanford Investigators
View full details
-
Targeted Therapy of Bronchiolitis Obliterans Syndrome
Not Recruiting
More
This phase II trial studies how well giving fluticasone propionate, azithromycin, and
montelukast sodium (FAM) together works in treating patients with bronchiolitis obliterans
who previously underwent stem cell transplant. FAM may be an effective treatment for
bronchiolitis obliterans
Stanford is currently not accepting patients for this trial.
For more information, please contact Physician Referrals, 650-723-0822.
Stanford Investigators
View full details
-
Transplantation for Patients With Chronic Lymphocytic Leukemia
Not Recruiting
More
To evaluate the role of high dose therapy and autologous or allogeneic hematopoietic cell
transplantation for the treatment of chronic lymphocytic leukemia.
Stanford is currently not accepting patients for this trial.
For more information, please contact BMT Referrals, 6507230822.
Lead Sponsor
Stanford Investigators
View full details
-
TLI & ATG for Non-Myeloablative Allogeneic Transplantation for MDS and MPD
Not Recruiting
More
To evaluate the feasibility and safety of TLI/ATG conditioning for allogeneic HCT for elderly
patients with advanced stage MDS and MPD.
Stanford is currently not accepting patients for this trial.
For more information, please contact Physician Referrals, 650-723-0822.
Lead Sponsor
Stanford Investigators
View full details
-
Acute Graft-versus-Host Disease Treatment (BMT CTN 0802)
Not Recruiting
More
The study is a Phase III, randomized double blind, placebo controlled, and trial evaluating
the addition of Mycophenolate mofetil (MMF) vs. placebo to systemic corticosteroids as
initial therapy for acute Graft Vs Host Disease (GVHD). The primary endpoint will be GVHD
free survival at Day 56 post randomization.
Stanford is currently not accepting patients for this trial.
For more information, please contact BMT Referrals, 6507230822.
Stanford Investigators
View full details
